1. Home
  2. HUBS vs MDGL Comparison

HUBS vs MDGL Comparison

Compare HUBS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HubSpot Inc.

HUBS

HubSpot Inc.

N/A

Current Price

$208.86

Market Cap

12.0B

Sector

Technology

ML Signal

N/A

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

N/A

Current Price

$413.48

Market Cap

11.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HUBS
MDGL
Founded
2005
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0B
11.5B
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
HUBS
MDGL
Price
$208.86
$413.48
Analyst Decision
Hold
Strong Buy
Analyst Count
34
19
Target Price
$225.53
★ $688.78
AVG Volume (30 Days)
★ 1.2M
531.3K
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 855.56
N/A
EPS
★ 3.12
N/A
Revenue
★ $375,612,000.00
$180,133,000.00
Revenue This Year
$17.75
$65.40
Revenue Next Year
$11.07
$37.87
P/E Ratio
$69.40
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$169.63
$353.54
52 Week High
$406.94
$615.00

Technical Indicators

Market Signals
Indicator
HUBS
MDGL
Relative Strength Index (RSI) 43.51 36.82
Support Level $183.62 $353.54
Resistance Level $260.19 $553.95
Average True Range (ATR) 13.73 24.41
MACD -0.69 2.85
Stochastic Oscillator 36.98 46.39

Price Performance

Historical Comparison
HUBS
MDGL

About HUBS HubSpot Inc.

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: